4075 related articles for article (PubMed ID: 22575324)
1. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
2. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
[TBL] [Abstract][Full Text] [Related]
3. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Skjøth F; Larsen TB; Rasmussen LH; Lip GY
Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
[TBL] [Abstract][Full Text] [Related]
5. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
6. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis.
Rasmussen LH; Larsen TB; Graungaard T; Skjøth F; Lip GY
BMJ; 2012 Nov; 345():e7097. PubMed ID: 23129490
[TBL] [Abstract][Full Text] [Related]
7. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Schneeweiss S; Gagne JJ; Patrick AR; Choudhry NK; Avorn J
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):480-6. PubMed ID: 22787066
[TBL] [Abstract][Full Text] [Related]
10. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
11. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Assiri A; Al-Majzoub O; Kanaan AO; Donovan JL; Silva M
Clin Ther; 2013 Jul; 35(7):967-984.e2. PubMed ID: 23870607
[TBL] [Abstract][Full Text] [Related]
12. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
Thromb Haemost; 2012 Mar; 107(3):584-9. PubMed ID: 22186961
[TBL] [Abstract][Full Text] [Related]
13. A review of oral anticoagulants in patients with atrial fibrillation.
Greenspon AJ
Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
[TBL] [Abstract][Full Text] [Related]
14. Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
Akwaa F; Spyropoulos AC
Hosp Pract (1995); 2013 Feb; 41(1):8-18. PubMed ID: 23466963
[TBL] [Abstract][Full Text] [Related]
15. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
Pisters R; Nieuwlaat R; Lane DA; Crijns HJ; Lip GY
Thromb Haemost; 2013 Feb; 109(2):328-36. PubMed ID: 23179181
[TBL] [Abstract][Full Text] [Related]
16. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Berman JP; Halperin JL
Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
Lenchus JD
Hosp Pract (1995); 2013 Feb; 41(1):49-60. PubMed ID: 23466967
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
[TBL] [Abstract][Full Text] [Related]
19. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
Miller CS; Grandi SM; Shimony A; Filion KB; Eisenberg MJ
Am J Cardiol; 2012 Aug; 110(3):453-60. PubMed ID: 22537354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]